



## **LMA International NV**

(Incorporated in the Netherland Antilles)

**22 December 2009**

### **Announcement to the Singapore Exchange**

#### **RESULTS OF EXTRAORDINARY GENERAL MEETING**

The Board of Directors of LMA International N.V. (the "Company") refers to the extraordinary general meeting (the "EGM") of the Company convened on 21 December 2009, for the purpose of seeking approval from shareholders of the Company ("Shareholders") for the proposed Shareholders' Mandate for Interested Person Transactions (the "Shareholders' Mandate").

The Board of Directors of the Company regrets to inform Shareholders that the Shareholders' Mandate was not approved.

Of the Shareholders eligible to vote at the EGM, 43 Shareholders representing 62,691,219 Shares or approximately 40 per cent. of the total number of votes voted at the EGM and 11.57 per cent. of the total issued share capital of the Company (excluding treasury shares) respectively, voted in favour of the Shareholders' Mandate and 2 Shareholders representing 95,212,000 Shares or approximately 60 per cent. of the total number of votes voted at the EGM and 17.57 per cent. of the total issued share capital of the Company (excluding treasury shares) respectively, voted against the resolution.

#### **CONSEQUENCES OF NON-APPROVAL OF THE SHAREHOLDERS' MANDATE**

As set out in the circular to Shareholders dated 4 December 2009 and in the Company's announcement dated 11 December 2009, the Company is not able to carry out transactions amounting to an aggregate value equal to, or more than 5 per cent. of its last audited net tangible assets with the same interested person (the "5% Limit") without the approval of shareholders being sought for each transaction under the listing rules of the Singapore Exchange Securities Trading Limited.

As the Company has to date utilised almost the maximum amount under the 5% Limit, it will not be able to continue to enter into further transactions with Forefront Medical Technology Pte Ltd ("FMT") without Shareholders' approval. As FMT is the Company's sole supplier of all the Company's single-use laryngeal mask devices which account for approximately 60 per cent. of the total revenue of the Company, this will disrupt the Company's business and affect the Company's operations and performance.

The seeking of Shareholders' approval for each additional transaction with FMT will be costly and will also increase the administrative time incurred to convene such meetings, and will have an adverse impact on the Company's business operations and performance.

## **ACTION BY THE COMPANY**

The Board of Directors of the Company is actively considering the appropriate actions to address the non-approval of the Shareholders' Mandate, including the convening of another EGM to seek the approval of Shareholders for specific transactions with FMT. The Company will, in compliance with the Corporate Disclosure Policy of the SGX-ST Listing Manual, make the relevant disclosures in due course.

BY ORDER OF THE BOARD

Robin Sims  
Company Secretary  
LMA International N.V.

### **LMA International NV**

Osprey House, Old Street, St. Helier, Jersey JE2 3RG, Channel Islands